FrontPage is India's Stock Market Social Network
Join 50,000+ Traders and Investors
forum

JAGSNPHARM Share Price Discussion

Jagsonpal Pharmaceuticals Ltd.
NSE: JAGSNPHARM | BSE: 507789 | ISIN: INE048B01027 | Sector: Pharmaceuticals and health care

JAGSNPHARM Rating

0/5 (0 Ratings)
JAGSNPHARM Share Price *
27.5 +0.5 (1.85%)
* (quote may be delayed)
Find answers to all your questions on live JAGSNPHARM message board: Is JAGSNPHARM buy or sell? Should I buy JAGSNPHARM shares? Why are JAGSNPHARM shares falling? Should I invest in JAGSNPHARM stock?

You can also check JAGSNPHARM share price target recommended by brokerages.

JAGSNPHARM Discussion Forum

@newsbot • Reputation: 2,308
Like
reply
Reply
@newsbot • Reputation: 2,308
Like
reply
Reply
  • JAGSNPHARM - Share Price - Fundamentals

    keyboard_arrow_down
    Market Capitalization68.91
    Enterprise Value34.17
    Price to Earnings8.41
    Price to Book Value0.66
    Return on Capital Employed-0.11
    Return on Equity-0.13
    Face Value5
    Dividend YieldNA
  • JAGSNPHARM Share Price - Technicals

    keyboard_arrow_down
    JAGSNPHARM - 52 Week High₹31.7
    JAGSNPHARM - 52 Week Low₹20.2
  • JAGSNPHARM Share Price - Historical (₹)

    keyboard_arrow_down
    DateOpenHighLowClose
    Feb 1925.927.4525.5527
    Feb 1826.226.925.626.35
    Feb 1726.527.7526.0526.5
    Feb 1428.428.427.127.2
    Feb 132728.82727.25
  • JAGSNPHARM Share Price - Daily Moving Averages (DMA)

    keyboard_arrow_down
    20 Day Moving Average₹27.24
    30 Day Moving Average₹27.29
    50 Day Moving Average₹26.59
    100 Day Moving Average₹25.99
    200 Day Moving Average₹25.48
  • JAGSNPHARM - Profit And Loss

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Revenue126.53143.87-0.12
    Operating Profit-11.115.76-2.93
    Profit Before Tax-11.6314.4-1.81
    Net Income-11.5511.86-1.97
  • JAGSNPHARM - Balance Sheet

    keyboard_arrow_down
    CONSOLIDATEDMar-19Mar-18 % Change
    Shareholder's Funds104.4790.210.16
    Total Liabilities31.3139.61-0.21
    Total Assets135.78129.820.05
  • JAGSNPHARM - Cash Flow

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Cash from Operating Activity-1.58-3.24-0.51
    Cash from Investing Activity-3.3741.29-1.08
    Cash from Financing Activity-0.6-33.52-0.98
    Net Cash Flow-5.554.53-2.23
  • JAGSNPHARM - Ratios

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17
    Return on Assets-0.090.08
    Return on Equity-0.130.12
    Return on Capital Employed-0.110.15
  • JAGSNPHARM - 3 year Growth

    keyboard_arrow_down
    3 Year CAGR Growth in Revenue-0.08
    3 Year CAGR Growth in Operating Profit-2.27
    3 Year CAGR Growth in EBIDTA-2.2
    3 Year CAGR Growth in Net Income-10.87
    3 Yr CAGR Growth - Diluted EPS-11.02
  • JAGSNPHARM - 5 year Growth

    keyboard_arrow_down
    5 Year CAGR Growth in Revenue-0.24
    5 Year CAGR Growth in Operating Profit-2.11
    5 Year CAGR Growth in EBIDTA-2.03
    5 Year CAGR Growth in Net Income-7.31
    3 Yr CAGR Growth - Diluted EPS-7.3
  • JAGSNPHARM - Recent News

    keyboard_arrow_down
  • JAGSNPHARM - Related Communities

    keyboard_arrow_down
    Sun Pharmaceutical Industries Ltd. S...
    Aurobindo Pharma Ltd. Sector: Pharma...
    Biocon Ltd. Sector: Pharmaceuticals ...
    Cipla Ltd. Sector: Pharmaceuticals a...
    Dr. Reddy's Laboratories Ltd. Sector...
    Lupin Ltd. Sector: Pharmaceuticals an...
    Piramal Enterprises Ltd. Sector: Phar...
    Divi's Laboratories Ltd. Sector: Pha...
    Glenmark Pharmaceuticals Ltd. Sector...
    Strides Pharma Science Ltd. Sector: P...
SOURCE: Data from D'Market via Quandl. Intraday data delayed 15 minutes.
DISCLAIMER: Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and FrontPage will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein.